ADAP - Adaptimmune Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-4.688M

Cash

204.7M

Avg Qtr Burn

-31.79M

Short % of Float

3.51%

Insider Ownership

0.30%

Institutional Own.

52.52%

Qtr Updated

06/30/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
afami-cel (Afamitresgene autoleucel) (ADP-A2M4) Details Myxoid/Round cell liposarcoma, Cancer	BLA Acceptance for review	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ADP-A2M4CD8 (MAGE A4) +/- nivolumab Details Cancer, Ovarian cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lete-cel (NY-ESO) Details Myxoid/Round cell liposarcoma, Sarcoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Gavo-cel (TC-210) (Mesothelin) + nivolumab Details Solid tumor/s, Ovarian cancer, Cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TC-510 Details Cancer, Ovarian cancer, Colorectal cancer , Pancreatic cancer, Mesothelioma, Triple-negative breast cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ADP-A2M4CD8 (MAGE A4) +/- nivolumab Details Head and neck cancer, Bladder cancer, Cancer, Solid tumor/s, Urothelial cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
afami-cel (afamitresgene autoleucel) (ADP-A2M4) + pembro Details Head and neck cancer, Homozygous familial hypercholesterolemia, Cancer, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TC-110 (CD19) Details Non-Hodgkin lymphoma, Leukemia, Acute lymphoblastic leukemia, Diffuse large B cell lymphoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ADP-A2AFP Details Hepatocellular carcinoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.